Description 5-Amino-1MQ, or 5-amino-1-methylquinolinium, is a novel small molecule compound that functions as a selective inhibitor of nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme predominantly active in adipose tissue. NNMT plays a crucial role in cellular energy homeostasis by regulating the levels of nicotinamide adenine dinucleotide (NAD ). Overexpression of NNMT is associated with obesity and type 2 diabetes, as it slows fat cell metabolism. By blocking the activity of NNMT, 5-Amino-1MQ increases the bioavailability of nicotinamide, a precursor to NAD , thereby elevating intracellular NAD levels. This elevation in NAD activates sirtuin-1 (SIRT1), often referred to as the “longevity gene,” which plays a vital role in DNA repair, inflammation reduction, and metabolic regulation. The subsequent increase in metabolic rate leads to a reduction in white adipose tissue and has been shown to produce significant weight loss in preclinical studies without affecting appetite. Furthermore, 5-Amino-1MQ has demonstrated a range of other potential therapeutic benefits, including: Lowering Cholesterol: Studies in diet-induced obese mice have shown that NNMT inhibition can lead to a reduction in total plasma cholesterol levels. Improving Blood Sugar Levels: By enhancing insulin sensitivity, 5-Amino-1MQ can help regulate blood sugar levels, making it a potential therapeutic for type 2 diabetes. Enhancing Aged Muscle Regeneration: 5-Amino-1MQ has been shown to promote the regeneration of aged muscle cells and may help treat muscle atrophy. Anti-Inflammatory Properties: The activation of SIRT1 by increased NAD levels contributes to anti-inflammatory effects. While research is ongoing, 5-Amino-1MQ’s unique mechanism of action presents a promising avenue for the treatment of obesity, metabolic syndrome, and other age-related conditions. Reported side effects are generally mild, but long-term safety data in humans is still limited. For research use only.
